{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tampa&page=23&state=Florida", "query": { "state": "Florida", "city": "Tampa", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 9115, "total_pages": 912, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tampa&page=24&state=Florida&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tampa&page=22&state=Florida&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T02:52:52.024Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Breast Cancer", "Breast Tumors", "Angiosarcoma", "TNBC - Triple-Negative Breast Cancer", "HER2-positive Breast Cancer", "HER2-negative Breast Cancer", "Hormone Receptor Positive Tumor", "Hormone Receptor Negative Tumor", "Early-stage Breast Cancer", "Locally Advanced Breast Cancer" ], "interventions": [ { "name": "Standard Therapy", "type": "DRUG" }, { "name": "AMG 386 with or without Trastuzumab", "type": "DRUG" }, { "name": "AMG 479 (Ganitumab) plus Metformin", "type": "DRUG" }, { "name": "MK-2206 with or without Trastuzumab", "type": "DRUG" }, { "name": "AMG 386 and Trastuzumab", "type": "DRUG" }, { "name": "T-DM1 and Pertuzumab", "type": "DRUG" }, { "name": "Pertuzumab and Trastuzumab", "type": "DRUG" }, { "name": "Ganetespib", "type": "DRUG" }, { "name": "ABT-888", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" }, { "name": "PLX3397", "type": "DRUG" }, { "name": "Pembrolizumab - 4 cycle", "type": "DRUG" }, { "name": "Talazoparib plus Irinotecan", "type": "DRUG" }, { "name": "Patritumab and Trastuzumab", "type": "DRUG" }, { "name": "Pembrolizumab - 8 cycle", "type": "DRUG" }, { "name": "SGN-LIV1A", "type": "DRUG" }, { "name": "Durvalumab plus Olaparib", "type": "DRUG" }, { "name": "SD-101 + Pembrolizumab", "type": "DRUG" }, { "name": "Tucatinib plus trastuzumab and pertuzumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Cemiplimab plus REGN3767", "type": "DRUG" }, { "name": "Trilaciclib with or without trastuzumab + pertuzumab", "type": "DRUG" }, { "name": "SYD985 ([vic-]trastuzumab duocarmazine)", "type": "DRUG" }, { "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab", "type": "DRUG" }, { "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab", "type": "DRUG" }, { "name": "Amcenestrant", "type": "DRUG" }, { "name": "Amcenestrant + Abemaciclib", "type": "DRUG" }, { "name": "Amcenestrant + Letrozole", "type": "DRUG" }, { "name": "ARX788", "type": "DRUG" }, { "name": "ARX788 + Cemiplimab", "type": "DRUG" }, { "name": "VV1 + Cemiplimab", "type": "DRUG" }, { "name": "Datopotamab deruxtecan", "type": "DRUG" }, { "name": "Datopotamab deruxtecan + Durvalumab", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Lasofoxifene", "type": "DRUG" }, { "name": "Z-endoxifen", "type": "DRUG" }, { "name": "ARV-471", "type": "DRUG" }, { "name": "ARV-471 + Letrozole", "type": "DRUG" }, { "name": "ARV-471 + Abemaciclib", "type": "DRUG" }, { "name": "Endoxifen + Abemaciclib", "type": "DRUG" }, { "name": "Rilvegostomig + TDXd", "type": "DRUG" }, { "name": "Dan222 + Niraparib", "type": "DRUG" }, { "name": "Sarilumab + Cemiplimab + Paclitaxel", "type": "DRUG" }, { "name": "GSK 5733584", "type": "DRUG" }, { "name": "GSK 5733584 + Dostarlimab", "type": "DRUG" }, { "name": "Ivonescimab (20mg/kg Q3W)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2010-03-01", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-11-01T02:52:52.024Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Davis", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01042379" }, { "nct_id": "NCT04964089", "title": "A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Wet Age-related Macular Degeneration" ], "interventions": [ { "name": "KSI-301", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" }, { "name": "Sham Procedure", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kodiak Sciences Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 557, "start_date": "2021-06-23", "completion_date": "2023-04-06", "has_results": true, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-11-01T02:52:52.024Z", "location_count": 65, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04964089" }, { "nct_id": "NCT03491150", "title": "An Open-Label Crenezumab Study in Participants With Alzheimer's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Crenezumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 149, "start_date": "2018-04-11", "completion_date": "2019-05-31", "has_results": true, "last_update_posted_date": "2020-07-13", "last_synced_at": "2026-11-01T02:52:52.024Z", "location_count": 32, "location_summary": "Newport Beach, California • Redlands, California • Sacramento, California + 28 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03491150" }, { "nct_id": "NCT00930774", "title": "Approaches to Auditory Rehabilitation for Mild Traumatic Brain Injury", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Traumatic Brain Injury" ], "interventions": [ { "name": "FM system", "type": "DEVICE" }, { "name": "Auditory training", "type": "BEHAVIORAL" } ], "intervention_types": [ "DEVICE", "BEHAVIORAL" ], "sponsor": "US Department of Veterans Affairs", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 99, "start_date": "2010-10", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2014-06-11", "last_synced_at": "2026-11-01T02:52:52.024Z", "location_count": 2, "location_summary": "Tampa, Florida • Portland, Oregon", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00930774" }, { "nct_id": "NCT03927274", "title": "Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Glioma of Brain" ], "interventions": [ { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-06-20", "completion_date": "2023-05-24", "has_results": false, "last_update_posted_date": "2023-05-25", "last_synced_at": "2026-11-01T02:52:52.024Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03927274" }, { "nct_id": "NCT00847613", "title": "A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "CP-690,550", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2009-03", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2024-05-16", "last_synced_at": "2026-11-01T02:52:52.024Z", "location_count": 37, "location_summary": "Huntsville, Alabama • Tucson, Arizona • San Diego, California + 32 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00847613" }, { "nct_id": "NCT02139124", "title": "The Efficacy and Safety of PRC-063 in Adult ADHD Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ADHD" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "PRC-063 25 mg", "type": "DRUG" }, { "name": "PRC-063 45 mg", "type": "DRUG" }, { "name": "PRC-063 70 mg", "type": "DRUG" }, { "name": "PRC-063 100 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rhodes Pharmaceuticals, L.P.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 375, "start_date": "2014-04", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2019-05-07", "last_synced_at": "2026-11-01T02:52:52.024Z", "location_count": 33, "location_summary": "Los Angeles, California • National City, California • Newport Beach, California + 27 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02139124" }, { "nct_id": "NCT02493868", "title": "A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depressive Disorder, Treatment-Resistant" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Duloxetine (Oral Antidepressant)", "type": "DRUG" }, { "name": "Escitalopram (Oral antidepressant)", "type": "DRUG" }, { "name": "Sertraline (Oral Antidepressant)", "type": "DRUG" }, { "name": "Venlafaxine Extended Release (XR) (Oral Antidepressant)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 719, "start_date": "2015-10-01", "completion_date": "2018-02-16", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-11-01T02:52:52.024Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02493868" }, { "nct_id": "NCT03898791", "title": "A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "LY3295668 Erbumine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2019-07-16", "completion_date": "2021-03-30", "has_results": false, "last_update_posted_date": "2021-08-05", "last_synced_at": "2026-11-01T02:52:52.024Z", "location_count": 16, "location_summary": "Fayetteville, Arkansas • Denver, Colorado • Tampa, Florida + 12 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03898791" }, { "nct_id": "NCT03468218", "title": "Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Head and Neck Carcinoma", "Paranasal Sinus Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Unresectable Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2018-09-18", "completion_date": "2026-10-29", "has_results": true, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-11-01T02:52:52.024Z", "location_count": 2, "location_summary": "Tampa, Florida • Atlanta, Georgia", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03468218" } ] }